# Myriad Genetics Inc. (MYGN) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $3.19, market value $305 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Myriad Genetics Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 0.4×**. Each dollar of revenue is priced at 0.4×, a low multiple typical of thin-margin businesses or out-of-favour stocks.
- **Price / book: 1.0×**. The shares trade at 1.0× book value; book value is a meaningful part of the valuation.

## Profitability
- **Gross margin: 68.8%**. Myriad Genetics Inc. keeps 68.8% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: -12.2%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -44.4%**. The company reported a net loss over the last twelve months.
- **Return on equity: -99.4%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -23.0%**. Return on all capital, debt included, is -23.0%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -15.9%**. Each dollar of assets produces -15.9% of profit.

## Growth
- **Revenue growth (1 yr): -1.6%** (3-yr 6.7%/yr, 5-yr 8.2%/yr). Revenue fell 1.6% over the last year, against 8.2% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): -180.1%**. Earnings per share fell 180.1%, slower than revenue, so margins compressed.

## Financial health
- **Debt to equity: 0.33**. Debt is 0.33 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 0.6×**. It would take 0.6 years of operating earnings to repay net borrowings, within the comfortable range.
- **Altman Z-score: 0.63**. A Z-score of 0.63 is in the distress zone, a signal to examine the balance sheet closely.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Myriad Genetics Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: hold** (8 analysts). 8 analysts cover Myriad Genetics Inc.; the consensus is hold, with an average price target of $3.34 (+5% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): -53.0%** (YTD -48.1%, 3-mo -30.2%). The shares are down 53.0% over twelve months including dividends.
- **From 52-week high: -62.9%** (16.4% above the low). Trading 63% below its 52-week high, deep in a drawdown.
- **200-day average: below**. The price sits below its 200-day moving average, the usual definition of a downtrend.
- **RSI (14-day): 39**. An RSI of 39 is neutral.
- **Beta (1 yr): 1.32** (volatility 79%). Beta of 1.32 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=MYGN · Page: https://foliofundamentals.com/stocks/mygn

Not investment advice.